CATALOGO DEI PRODOTTI DELLA RICERCA
IRIS è la soluzione IT che facilita la raccolta e la gestione dei dati relativi alle attività e ai prodotti della ricerca. Fornisce a ricercatori, amministratori e valutatori gli strumenti per monitorare i risultati della ricerca, aumentarne la visibilità e allocare in modo efficace le risorse disponibili.
EnglishBackground: Concomitant hepatitis C virus infection (HCV) needs caution when selecting systemic treatments in psoriasis patients as some agents confer a risk of liver toxicity and/or are immunosuppressant. Phototherapy may provide a therapeutic choice but it is not always a practical option. Limited evidence supports the use of cyclosporine or TNF-alpha blockers. No data are available concerning the safety of efalizumab in patients with HCV infection. Objective: To describe the clinical characteristics and evolution of 5 adult patients with severe chronic plaque psoriasis and concomitant HCV infection who were treated with efalizumab. Method: A retrospective clinical case report. Results: Five adult patients with severe chronic plaque psoriasis and concomitant HCV infection were treated successfully using efalizumab with no increased viral replication and progression of liver disease for a follow-up of 8-20 months. Conclusion: Although further confirmation is needed, this report provides preliminary evidence to support also a cautious use of efalizumab in patients with HCV infection. Copyright (C) 2009 S. Karger AG, Basel
Treatment of psoriasis with efalizumab in patients with hepatitis C virus infection: report of five cases / Gisondi P; Prignano F; Grossi P; Lotti T; Girolomoni G. - In: DERMATOLOGY. - ISSN 1051-8258. - STAMPA. - 219(2009), pp. 158-161.
| Titolo: | Treatment of psoriasis with efalizumab in patients with hepatitis C virus infection: report of five cases |
| Autori: | |
| Data di pubblicazione: | 2009 |
| Rivista: | |
| Citazione: | Treatment of psoriasis with efalizumab in patients with hepatitis C virus infection: report of five cases / Gisondi P; Prignano F; Grossi P; Lotti T; Girolomoni G. - In: DERMATOLOGY. - ISSN 1051-8258. - STAMPA. - 219(2009), pp. 158-161. |
| Abstract: | Background: Concomitant hepatitis C virus infection (HCV) needs caution when selecting systemic treatments in psoriasis patients as some agents confer a risk of liver toxicity and/or are immunosuppressant. Phototherapy may provide a therapeutic choice but it is not always a practical option. Limited evidence supports the use of cyclosporine or TNF-alpha blockers. No data are available concerning the safety of efalizumab in patients with HCV infection. Objective: To describe the clinical characteristics and evolution of 5 adult patients with severe chronic plaque psoriasis and concomitant HCV infection who were treated with efalizumab. Method: A retrospective clinical case report. Results: Five adult patients with severe chronic plaque psoriasis and concomitant HCV infection were treated successfully using efalizumab with no increased viral replication and progression of liver disease for a follow-up of 8-20 months. Conclusion: Although further confirmation is needed, this report provides preliminary evidence to support also a cautious use of efalizumab in patients with HCV infection. Copyright (C) 2009 S. Karger AG, Basel |
| Handle: | http://hdl.handle.net/11562/339240 |
| Appare nelle tipologie: | 01.01 Articolo in Rivista |
File in questo prodotto:
http://hdl.handle.net/11562/339240
Copyright © 2021